PRESENTATION ON NW BIO'S DCVAX-DIRECT TRIAL ANNOUNCED FOR ASCO ANNUAL MEETING

[PR Newswire] – BETHESDA, Md., April 22, 2014 /PRNewswire/ — Northwest Biotherapeutics (NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers…Read More »

NW BIO CLOSES ON FIRST $15 MILLION OF FINANCING FOR SUBSTANTIAL EXPANSION OF EUROPEAN PRODUCTION CAPACITY

[PR Newswire] – BETHESDA, Md., April 15, 2014 /PRNewswire/ — Northwest Biotherapeutics (NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers…Read More »

Nasdaq stocks posting largest percentage decreases

NORTHWEST BIOTHERAPEUTICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Eq

When is a Warrant Not a Warrant? When Northwest Bio is Raising Money.

Northwest Biotherapeutics (NASDQ: NWBO) is developing cancer vaccines designed to treat a broad range of solid tumor cancers more effectively than current treatments, and without the side effects of chemotherapy drugs.

Company Information

Company Website: http://www.nwbio.com/
Company Headquarters

4800 Montgomery Lane, Suite 800
Bethesda, MD 20814
Phone: (240) 497-9024

Media Contact

Les Goldman
Phone: (202) 841-7909
lgoldman@nwbio.com

Farrell Kramer
(212) 710-9685
farrell.kramer@mbsvalue.com

Investor Relations Contact

Les Goldman
Phone: (202) 841-7909
lgoldman@nwbio.com

Lisa Sher
(212) 661-2220
lisa.sher@mbsvalue.com

Forward Looking Statements

Statements made in this news release that are not historical facts, including statements concerning future treatment of patients using DCVax and future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “expect,” “believe,” “intend,” “design,” “plan,” “continue,” “may,” “will,” “anticipate,” and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as risks related to the use of proceeds; the exercise of the Overallotment Right and the satisfaction of customary closing conditions for such exercise; the Company’s ability to raise additional capital, risks related to the Company’s ability to enroll patients in its clinical trials and complete the trials on a timely basis, uncertainties about the clinical trials process, uncertainties about the timely performance of third parties, risks related to whether the Company’s products will demonstrate safety and efficacy, risks related to the Company’s and Cognate’s abilities to carry out the intended manufacturing expansions contemplated in the Cognate Agreements, risks related to the Company’s ability to carry out the Hospital Exemption program and risks related to possible reimbursement and pricing. Additional information on these and other factors, including Risk Factors, which could affect the Company’s results, is included in its Securities and Exchange Commission (“SEC”) filings. Finally, there may be other factors not mentioned above or included in the Company’s SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.

This Blog is official and sanctioned by Northwest Biotherapeutics | See Disclaimer | See Privacy Policy